Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at HC Wainwright

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 79.10% from the company’s current price.

Several other research firms have also issued reports on TRVI. Raymond James initiated coverage on Trevi Therapeutics in a research report on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target on the stock. B. Riley reissued a “buy” rating and issued a $6.00 price target on shares of Trevi Therapeutics in a research note on Monday, October 7th. EF Hutton Acquisition Co. I raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, August 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Trevi Therapeutics in a research report on Friday, October 4th. Finally, Leerink Partners assumed coverage on Trevi Therapeutics in a research report on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Trevi Therapeutics presently has an average rating of “Buy” and an average price target of $7.43.

Trevi Therapeutics Trading Up 7.4 %

Shares of TRVI opened at $3.35 on Tuesday. Trevi Therapeutics has a 1 year low of $0.97 and a 1 year high of $4.00. The stock has a 50 day simple moving average of $3.09 and a 200-day simple moving average of $2.89. The stock has a market cap of $235.96 million, a PE ratio of -9.85 and a beta of 0.97.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same quarter in the prior year, the business earned ($0.07) earnings per share. On average, sell-side analysts forecast that Trevi Therapeutics will post -0.47 EPS for the current fiscal year.

Insider Activity

In other news, CEO Jennifer L. Good sold 10,981 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the transaction, the chief executive officer now owns 213,313 shares of the company’s stock, valued at approximately $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Jennifer L. Good sold 10,981 shares of the stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total transaction of $33,162.62. Following the sale, the chief executive officer now owns 213,313 shares of the company’s stock, valued at $644,205.26. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.76, for a total value of $51,501.60. Following the sale, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,355 shares of company stock valued at $116,663. 24.37% of the stock is owned by insiders.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of TRVI. Oppenheimer & Co. Inc. acquired a new stake in shares of Trevi Therapeutics in the 1st quarter valued at $208,000. Vanguard Group Inc. boosted its holdings in shares of Trevi Therapeutics by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock valued at $7,948,000 after purchasing an additional 60,249 shares in the last quarter. Propel Bio Management LLC acquired a new stake in shares of Trevi Therapeutics in the 1st quarter valued at $897,000. Price T Rowe Associates Inc. MD acquired a new stake in shares of Trevi Therapeutics in the 1st quarter valued at $47,000. Finally, Opaleye Management Inc. boosted its holdings in shares of Trevi Therapeutics by 4.3% in the 1st quarter. Opaleye Management Inc. now owns 2,645,000 shares of the company’s stock valued at $9,125,000 after purchasing an additional 110,000 shares in the last quarter. Institutional investors and hedge funds own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.